## The Evolution of Personal genetic Testing: From Clinic to Consumer
Over the last twenty years, the landscape of genetic testing for disease predisposition has undergone a meaningful shift, moving from traditional clinical settings directly into the hands of consumers. This change was initially sparked in the early 2000s by the emergence of direct-to-consumer (DTC) genetic testing, empowering individuals to purchase tests and interpret results independently, bypassing the need for a healthcare professional. The global market for genetic testing was valued at approximately $28.19 billion in 2023 and is projected to reach $56.69 billion by 2032[1], demonstrating the rapid growth and increasing accessibility of these services.
### The Rise of Physician-Mediated Testing
By the mid-2010s, a hybrid approach – physician-mediated genetic testing – began to gain prominence. This model sought to bridge the gap between the convenience of DTC testing and the perceived authority of clinical oversight. It allows consumers to initiate the testing process online, while a physician, often sourced from a third-party network, formally authorizes the order[1, 2]. Currently, physician-mediated testing continues its expansion, offering a diverse range of options, from panels analyzing multiple genes related to cancer and heart disease to comprehensive whole-genome sequencing. Several companies now extend their services internationally, with availability in countries beyond the United States[3].
### A Question of Oversight: DTC in Disguise?
While presented as a more responsible option to traditional DTC testing, particularly in the United States, physician-mediated genetic testing often lacks ample clinical oversight. The involvement of a physician is frequently limited to simply approving the test request, with minimal or no direct consultation or interaction with the patient.Consequently, from the consumer’s viewpoint, the experience closely mirrors that of DTC testing. The perceived medical guidance is often superficial, leading to the conclusion that physician-mediated genetic testing is, for all practical purposes, DTC testing rebranded. This raises concerns about the appropriate interpretation of results and the potential for uninformed healthcare decisions.